Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND: Trastuzumab Deruxtecan Tailoring by Liquid Biopsy
2024-518017-26-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Policlinico Gemelli. Primary endpoint: Concordance in progression between RECIST v1.1 and ctDNA at 1 year. Planned start Nov 2024; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-518017-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518017-26-00.